

28 February 2025

Updated Appendices 3X and 3Y

Enlitic, Inc. (ASX: ENL) (“the Company”) attaches the following updated Appendices:

- Appendix 3X “Initial Director’s Interests Notification” replacing the Appendix 3X lodged with ASX on 20 December 2023; and
- Appendix 3Y “Change of Director’s Interest Notice” for Mr Lawrence Gozlan lodged with ASX on 22 January 2025 (together “**Appendices**”).

The above Appendices have been updated to include shares of common stock that were acquired by Mr Gozlan during the IPO.

Following a thorough review undertaken by the Company in relation to quoted and unquoted securities on issue, it was noted that the common stock acquired by Mr Gozlan during the IPO had been inadvertently omitted from these Appendices due to an administrative oversight.

The Company confirms this was an isolated incident and that it has internal procedures and processes in place to meet its disclosure obligations required by ASX Listing Rules 3.19A and 3.19B.

– ENDS –

This announcement was authorised for release by the Company Secretary.

Enquiries:

Enlitic Investor Relations

Australia:
invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

Read more at enlitic.com.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Enlitic, Inc. (ASX: ENL)
ARBN:	672 254 027

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lawrence Gozlan
Date of appointment	23 September 2019

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

51,341 options at US\$1.16. Expiry date: 6 June 2029.
40,000 options at US\$2.32. Expiry date: 30 July 2030.
86,653 options at US\$2.75. Expiry date: 19 December 2031.
2,500,000 options at US\$0.11. Expiry date: 29 May 2033.
177,994 options at US\$0.35. Expiry date: 11 September 2033.
6,800,000 options at A\$0.07. Expiry date 16 January 2035.

60,241 Shares of Common Stock

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Number & class of Securities
N/A	N/A

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Enlitic, Inc (ASX:ENL)
ARBN	672 254 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lawrence Gozlan
Date of last notice	20 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	16 January 2025
No. of securities held prior to change	51,341 options at US\$1.16. Expiry date: 6 June 2029. 40,000 options at US\$2.32. Expiry date: 30 July 2030. 86,653 options at US\$2.75. Expiry date: 19 December 2031. 2,500,000 options at US\$0.11. Expiry date: 29 May 2033. 177,994 options at US\$0.35. Expiry date: 11 September 2033. 60,241 Shares of Common Stock

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Options
Number acquired	6,800,000 options over shares with each option exercisable at A\$0.07 and an expiry date of 16 January 2035.
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>51,341 options at US\$1.16. Expiry date: 6 June 2029.</p> <p>40,000 options at US\$2.32. Expiry date: 30 July 2030.</p> <p>86,653 options at US\$2.75. Expiry date: 19 December 2031.</p> <p>2,500,000 options at US\$0.11. Expiry date: 29 May 2033.</p> <p>177,994 options at US\$0.35. Expiry date: 11 September 2033.</p> <p>6,800,000 options at A\$0.07. Expiry date 16 January 2035.</p> <p>60,241 Shares of Common Stock</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Options under the Company's 2023 Equity Incentive Plan, as approved by shareholders at the EGM held on 14 January 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.